Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons.
Rebif® (interferon-beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. Efficacy of Rebif® in chronic progressive multiple sclerosis has not been established.
Published Studies Related to Rebif (Interferon Beta-1A)
Comparing efficacy and side effects of a weekly intramuscular
biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting
multiple sclerosis: a double blind randomized clinical trial. 
USA) and CinnoVex (CinnaGen, Iran)... CONCLUSION: CinnoVex can be used as a safe and effective alternative to Avonex in
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year
follow-up of the ASA cohort. 
combined with low-dose azathioprine and prednisone in multiple sclerosis... CONCLUSION: The tested combined therapeutic regimen does not improve long-term
Interferon beta for secondary progressive multiple sclerosis. 
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients
A novel PEGylated interferon beta-1a for multiple sclerosis: safety,
pharmacology, and biology. 
This study clinically evaluated a novel PEGylated form of interferon beta-1a
(PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple
sclerosis, in healthy volunteers. Two randomized, blinded phase I studies were
conducted: a single-dose study (n = 60) comparing subcutaneous or intramuscular
PEG-IFN beta-1a (63, 125, or 188 µg) with intramuscular unmodified IFN beta-1a 30
µg and a multiple-dose study (n = 69) comparing subcutaneous PEG-IFN beta-1a
dosed once every 2 or 4 weeks with placebo...
Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. [2011.12.15]
Recent studies have demonstrated the immunomodulatory properties of vitamin D, and vitamin D deficiency may be a risk factor for the development of MS. The risk of developing MS has, in fact, been associated with rising latitudes, past exposure to sun and serum vitamin D status...
Clinical Trials Related to Rebif (Interferon Beta-1A)
Rebif New Formulation (RNF) Quality of Life Study [Active, not recruiting]
To evaluate the impact on Quality of Life, tolerability, treatment satisfaction, and
injection site redness Rebif treated subjects with relapsing forms of MS who transition to a
new formulation of Rebif.
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis [Completed]
The purpose of this study is to find out if weekly Avonex works as well as three times a week
Rebif in subjects with relapsing multiple sclerosis.
Transition to Rebif New Formulation [Active, not recruiting]
To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients
with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon
beta-1a, 44mcg three-times-weekly) to the new formulation of Rebif while receiving ibuprofen
either prophylactically or only when necessary (PRN) after the occurance of flu-like
Avonex (Interferon-Beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-Remitting MS [Active, not recruiting]
The primary objective of this study is to determine whether combination treatment (adding
methylprednisolone to Avonex) reduces progression of disability over 4 years compared to
Avonex alone. The study will also investigate whether combination therapy has any impact on
the incidence of relapse and brain atrophy as measured by MRI.
Phase II Cladribine Add-on to Inteferon-Beta (IFN-b) Therapy in MS Subjects With Active Disease [Recruiting]
The goal of this study is to evaluate the safety, tolerability and effectiveness of oral
cladribine when taken in combination with Interferon-beta therapy for the treatment of MS.
This study will randomize 200 subjects from approximately 50 sites located world-wide, who
have experienced at least one relapse while taking Interferon-beta therapy within 48 weeks
prior to Screening, irrespective of disability progression. Secondary progressive multiple
sclerosis (SPMS) patients, who are still experiencing relapses, and patients who have
received disease modifying drugs (DMDs), other than Interferon-beta therapy, during their MS
treatment history, but are currently on Interferon-beta therapy and have experienced active
MS symptoms (at least 1 relapse) during the 48 weeks prior to Screening, may also be
Subjects will be randomised in a 2: 1 fashion to receive up to 4 cycles of oral cladribine or
matching placebo in combination with Interferon-beta therapy. Total subject participation is
Reports of Suspected Rebif (Interferon Beta-1A) Side Effects
Injection Site Erythema (716),
Multiple Sclerosis Relapse (680),
Injection Site Pain (519),
Influenza Like Illness (489),
Injection Site Haematoma (335),
Depression (265), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Rebif has an overall score of 6. The effectiveness score is 8 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
Rebif review by 29 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || Multiple Sclerosis|
|Dosage & duration:|| || 250 mg taken 3x weekly for the period of 18 months|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Reduce number of MS relapses|
|Side effects:|| || Flu like symptoms- aches, fever|
|Comments:|| || subcutaneous injection 3x weekly|
Page last updated: 2013-02-10